Oral administration of artemisone for the treatment of schistosomiasis: Formulation challenges and in vivo efficacy

Johanna Zech, Daniel Gold, Nadeen Salaymeh, Netanel Cohen Sasson, Ithai Rabinowitch, Jacob Golenser*, Karsten Mäder

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

Artemisone is an innovative artemisinin derivative with applications in the treatment of malaria, schistosomiasis and other diseases. However, its low aqueous solubility and tendency to degrade after solubilisation limits the translation of this drug into clinical practice. We developed a self-microemulsifying drug delivery system (SMEDDS), which is easy to produce (simple mixing) with a high drug load. In addition to known pharmaceutical excipients (Capmul MCM, Kolliphor HS15, propylene glycol), we identified Polysorb ID 46 as a beneficial new additional excipient. The physicochemical properties were characterized by dynamic light scattering, conductivity measurements, rheology and electron microscopy. High storage stability, even at 30°C, was achieved. The orally administrated artemisone SMEDDS formulation was highly active in vivo in S. mansoni infected mice. Thorough elimination of the adult worms, their eggs and prevention of the deleterious granuloma formation in the livers of infected mice was observed even at a relatively low dose of the drug. The new formulation has a high potential to accelerate the clinical use of artemisone in schistosomiasis and malaria.

Original languageEnglish
Article number509
JournalPharmaceutics
Volume12
Issue number6
DOIs
StatePublished - Jun 2020

Keywords

  • Artemisone
  • Lipid
  • Microemulsion
  • Oral
  • SMEDDS
  • SNEDDS
  • Schistosomiasis
  • Self-microemulsifying

Fingerprint

Dive into the research topics of 'Oral administration of artemisone for the treatment of schistosomiasis: Formulation challenges and in vivo efficacy'. Together they form a unique fingerprint.

Cite this